Evidence map›Paper›PMID 31622442›Full record

ArticlePLoS pathogens2019

Fosmidomycin, an inhibitor of isoprenoid synthesis, induces persistence in Chlamydia by inhibiting peptidoglycan assembly.

Jessica A Slade, Mary Brockett, Raghuveer Singh, George W Liechti, Anthony T Maurelli

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. TheApplied and environmental microbiology · 2024
    Article
  7. Infection and immunity · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Localized Peptidoglycan Biosynthesis inFrontiers in microbiology · 2021
    Article
  17. Robust Heat Shock Response inFrontiers in microbiology · 2021
    Article
  18. Article
  19. Transcriptional Landscape ofMicroorganisms · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jessica A SladeEmerging Pathogens Institute and Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, United States of America.
Mary BrockettDepartment of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, Maryland, United States of America.ORCID 0000-0002-5167-9231
Raghuveer SinghEmerging Pathogens Institute and Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, United States of America.
George W LiechtiDepartment of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, Maryland, United States of America.ORCID 0000-0003-3028-8474
Anthony T MaurelliEmerging Pathogens Institute and Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, United States of America.
University of Florida · USUniformed Services University of the Health Sciences · US

Funding

MOLECULAR GENETIC ANALYSIS OF CHLAMYDIA PATHOGENICITYR01AI044033 · NIAID · UNIVERSITY OF FLORIDA · PI MAURELLI, ANTHONY T · 1999 to 2016
$3.9M
Peptidoglycan Assembly, Degradation, and Function in Pathogenic ChlamydiaR01AI123300 · NIAID · UNIVERSITY OF FLORIDA · PI MAURELLI, ANTHONY T · 2017 to 2021
$1.9M
NIAID NIH HHS R01 AI044033NIAID NIH HHS R01 AI123300
6 · The paper itself

Abstract

The antibiotic, fosmidomycin (FSM) targets the methylerythritol phosphate (MEP) pathway of isoprenoid synthesis by inhibiting the essential enzyme, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr) and is lethal to intracellular parasites and bacteria. The obligate intracellular bacterial pathogen, Chlamydia trachomatis, alternates between two developmental forms: the extracellular, infectious elementary body (EB), and the intracellular, replicative form called the reticulate body (RB). Several stressful growth conditions including iron deprivation halt chlamydial cell division and cause development of a morphologically enlarged, but viable form termed an aberrant body (AB). This phenotype constitutes the chlamydial developmental state known as persistence. This state is reversible as removal of the stressor allows the chlamydiae to re-enter and complete the normal developmental cycle. Bioinformatic analysis indicates that C. trachomatis encodes a homolog of Dxr, but its function and the requirement for isoprenoid synthesis in chlamydial development is not fully understood. We hypothesized that chlamydial Dxr (DxrCT) is functional and that the methylerythritol phosphate (MEP) pathway is required for normal chlamydial development. Thus, FSM exposure should be lethal to C. trachomatis. Overexpression of chlamydial Dxr (DxrCT) in Escherichia coli under FSM exposure and in a conditionally lethal dxr mutant demonstrated that DxrCT functions similarly to E. coli Dxr. When Chlamydia-infected cultures were exposed to FSM, EB production was significantly reduced. However, titer recovery assays, electron microscopy, and peptidoglycan labeling revealed that FSM inhibition of isoprenoid synthesis is not lethal to C. trachomatis, but instead induces persistence. Bactoprenol is a critical isoprenoid required for peptidoglycan precursor assembly. We therefore conclude that FSM induces persistence in Chlamydia by preventing bactoprenol production necessary for peptidoglycan precursor assembly and subsequent cell division.

Indexed as

Aldose-Ketose IsomerasesAnti-Bacterial AgentsCell Line, TumorChlamydia InfectionsChlamydia trachomatisEscherichia coliFosfomycinHeLa CellsHumansPeptidoglycanTerpenes1-deoxy-D-xylulose 5-phosphate reductoisomeraseAldose-Ketose IsomerasesAnti-Bacterial AgentsbactoprenolFosfomycinfosmidomycinPeptidoglycanTerpenes

Identifiers

PMID31622442
PMCPMC6818789
OpenAlexW2980581135

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.